modelFamotidine
Extends from Pharmacolibrary.Drugs.ATC.A.A02BA03.
Information
| name: | Famotidine | |
| ATC code: | A02BA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 40 | mg |
| volume of distribution: | 1.1 | L |
| clearance: | 413 | mL/min |
| other parameters in model implementation | ||
Famotidine is a histamine H2 receptor antagonist used to reduce stomach acid production. It is commonly indicated for the treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD), and conditions that cause excessive stomach acid such as Zollinger-Ellison syndrome. Famotidine is approved and widely used today both as a prescription and over-the-counter medication.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers after a single 40 mg oral dose.
References
McCann, S, et al., & Gonzalez, D (2023). Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease. Clinical pharmacokinetics 62(7) 997–1009. DOI:10.1007/s40262-023-01254-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37179512
Avner, DL (2000). Clinical experience with pantoprazole in gastroesophageal reflux disease. Clinical therapeutics 22(10) 1169–1150. DOI:10.1016/s0149-2918(00)83061-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11110229
Shaefer, MS, et al., & Stratta, RJ (1995). Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. The Annals of pharmacotherapy 29(11) 1088–1091. DOI:10.1177/106002809502901102 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8573949
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)